Analytical Data
-
Gene name
Latent TGF beta 1/TGFB1
- Application
-
Alternative Names
TGF-B1; CED; DPD1; LAP; Camurati-Engelmann Disease; Latency-associated peptide
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 85% as determined by SDS-PAGE.
-
Uniprot
P01137
-
Expression Region
Leu30~Ser390
-
Protein Length
Partial
-
Molecular Weight
43kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Latent TGF-beta 1 (TGFB1) is a member of the TGF-beta superfamily, recognized for its crucial role in regulating various cellular processes, including cell proliferation, differentiation, and immune responses. It exists in a latent form, sequestered in the extracellular matrix, which prevents premature activation. The activation of latent TGF-beta 1 is a fundamental step in various physiological and pathological processes, such as wound healing, fibrosis, and cancer progression. Given its significant implications in these areas, recombinant forms of latent TGF-beta 1 have been generated for research purposes. These recombinant proteins serve as valuable tools for elucidating the mechanisms of TGF-beta activation and signaling pathways, which can lead to the development of novel therapeutic strategies targeting TGF-beta related diseases. Additionally, understanding the structural and functional aspects of latent TGF-beta 1 is essential for designing effective interventions to modulate its activity in various disease states. Overall, the study of recombinant latent TGF-beta 1 contributes to advancing our knowledge in cellular biology and therapeutic applications.
